About Glympse Bio
Glympse Bio is a company based in Cambridge (United States) founded in 2015 was acquired by Sunbird Bio in August 2023.. Glympse Bio has raised $79.39 million across 6 funding rounds from investors including Gilead, New Leaf Venture Partners and Sunbird Bio. The company has 21 employees as of December 31, 2022. Glympse Bio operates in a competitive market with competitors including Alamar Biosciences, Harmonic Discovery, Seahorse Bioscience, Luceome Biotechnologies and BiOD, among others.
- Headquarter Cambridge, United States
- Employees 21 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$79.39 M (USD)
in 6 rounds
-
Latest Funding Round
$46.7 M (USD), Series B
May 29, 2020
-
Investors
Gilead
& 18 more
-
Employee Count
21
as on Dec 31, 2022
-
Acquired by
Sunbird Bio
(Aug 09, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Glympse Bio
Glympse Bio has successfully raised a total of $79.39M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $46.7 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $46.7M
-
First Round
First Round
(01 Jun 2015)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Series B - Glympse Bio | Valuation | Section 32 | |
| Jun, 2019 | Amount | Grant - Glympse Bio | Valuation |
investors |
|
| Jul, 2018 | Amount | Series A - Glympse Bio | Valuation | Polaris Partners , Arch Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Glympse Bio
Glympse Bio has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Gilead, New Leaf Venture Partners and Sunbird Bio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative technology startups.
|
Founded Year | Domain | Location | |
|
An investment platform is provided for diverse sectors and geographies.
|
Founded Year | Domain | Location | |
|
US private equity investments are managed by DNS Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Glympse Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Glympse Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Glympse Bio Comparisons
Competitors of Glympse Bio
Glympse Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alamar Biosciences, Harmonic Discovery, Seahorse Bioscience, Luceome Biotechnologies and BiOD, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Ultra-high sensitivity protein analysis solutions are provided across multiplex levels.
|
|
| domain | founded_year | HQ Location |
Developer of kinase inhibitor drugs for oncology
|
|
| domain | founded_year | HQ Location |
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
|
|
| domain | founded_year | HQ Location |
Assay technology is developed for identifying drugs against kinases.
|
|
| domain | founded_year | HQ Location |
Develops innovative in-vitro diagnostic platforms using optical interrogation of biochip-kits.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Glympse Bio
Frequently Asked Questions about Glympse Bio
When was Glympse Bio founded?
Glympse Bio was founded in 2015.
Where is Glympse Bio located?
Glympse Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Glympse Bio a funded company?
Glympse Bio is a funded company, having raised a total of $79.39M across 6 funding rounds to date. The company's 1st funding round was a Series A of $26.09M, raised on Jun 01, 2015.
How many employees does Glympse Bio have?
As of Dec 31, 2022, the latest employee count at Glympse Bio is 21.
What does Glympse Bio do?
Glympse Bio was founded in 2015 in Cambridge, United States, within the biotechnology sector focused on diagnostics. Noninvasive and predictive monitoring of various human diseases is facilitated by engineered diagnostic sensors that detect disease states in the body. Urine samples are analyzed using customized delivery routes and multiplexed analytical platforms. Operations emphasize urine-based interrogation for early disease identification across multiple conditions.
Who are the top competitors of Glympse Bio?
Glympse Bio's top competitors include Alamar Biosciences, Harmonic Discovery and Seahorse Bioscience.
Who are Glympse Bio's investors?
Glympse Bio has 19 investors. Key investors include Gilead, New Leaf Venture Partners, Sunbird Bio, HHS, and Temasek.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.